Neoadjuvant chemotherapy for invasive bladder cancer (Q37982318)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on April 2012

Language	Label	Description	Also known as
English	Neoadjuvant chemotherapy for invasive bladder cancer	scientific article published on April 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Neoadjuvant chemotherapy for invasive bladder cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

based on heuristic

inferred from title

2

object named as

Cora N Sternberg

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Guru Sonpavde

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

1 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Current urology reports

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

136-146

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Natural history of surgically treated bladder carcinoma with extravesical tumor extension.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Bladder cancer: narrowing the gap between evidence and practice

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Surgical factors influence bladder cancer outcomes: a cooperative group report

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Adjuvant chemotherapy in lymph node positive bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Precystectomy nomogram for prediction of advanced bladder cancer stage.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Urothelial tumorigenesis: a tale of divergent pathways

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Generation of a concise gene panel for outcome prediction in urinary bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11934-012-0236-2

21 January 2018

Molecular mediators of angiogenesis in bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of amplification of c-erb-B2 in bladder carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line chemotherapy for advanced urothelial cancer: because we should or because we can?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of circulating tumor cells in patients with urothelial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative chemotherapy for bladder cancer: a standard waits to be optimally deployed

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant chemotherapy in muscle-invasive bladder carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22314880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11934-012-0236-2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37982318&oldid=2201136343"